Last updated on March 2009

Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Community-Acquired Pneumonia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Male or female patients aged 18 years or above.
    Patients who are willing and able to provide written informed consent.
    Accord with the diagnosis criteria of CAP based on clinical, radiological and
    microbiological findings.
    With aspiration factors (Including swallowing or coughing reflection test positive)

You may not be eligible for this study if the following are true:

  • Known hypersensitivity to fluoroquinolones and/or metronidazole.
    Female patients who are pregnant or lactating.
    Patients with mechanical ventilation lasting more than 48 hours prior to enrollment.
    Patients with neutropenia (neutrophil count <1.000/mm3) due to malignancy or
    chemotherapy.
    Patients with a severe, life-threatening disease with a life expectancy of less than
    2 months.
    Patients with a co-existent disease considered likely to affect the outcome of the
    tudy (e.g. lung cancer, cystic fibrosis, collagen vascular disease affecting the
    lungs, pleural empyema, severe cardiac failure class III or IV of the NYHA).
    Patients with poststenotic pneumonia (e.g. in connection with carcinoma of the lung).
    Patients with acute infarction pneumonia.
    Patients with active pulmonary tuberculosis.
    Patients with lung abscess/pneumonia with concomitant endocarditis.
    Patients with known i.v. drug abuse.
    Patients known to have AIDS (CD4 count <200/ul) or HIV-seropositives who are
    receiving HAART (highly activated antiretroviral therapy). Note: HIV-positive
    patients may be included. HIV testing is not required for this study protocol.
    Patients with severe hepatic impairment (Child-Pugh C).
    Patients on hemodialysis, equivalent to creatinine clearance <15 ml/min/1.73 m2.
    Patients known to have congenital or sporadic syndromes of QTc prolongation, or are
    receiving concomitant medication reported to increase the QTc interval, e.g.
    amiodaron, sotalol, disopyramide, quinidine, procainamide, terfenadine.
    Previous history of tendinopathy with quinolones.
    Patients who have previously been included in this study.
    Patients with any investigational drug within 30 days of screening.
    Patients requiring concomitant systemic antibacterial agents.
    Pre-treatment with a systemic antibacterial agent within 24 hours prior to enrollment
    (Except for the cases that pre-treatment is not effective based on the clinical
    judgment).
    Severe CAP.
    Other contraindications in package insert.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.